Welcome to our dedicated page for Neurosense Therapeutics news (Ticker: NRSN), a resource for investors and traders seeking the latest updates and insights on Neurosense Therapeutics stock.
NeuroSense Therapeutics Ltd. develops therapies for severe neurodegenerative diseases, led by PrimeC, a proprietary fixed-dose oral extended-release combination of ciprofloxacin and celecoxib. Company news centers on PrimeC clinical and biomarker data in amyotrophic lateral sclerosis, Alzheimer’s disease program updates, regulatory interactions, and scientific publications or conference presentations related to the PARADIGM and PARAGON programs.
Recurring developments also include intellectual-property coverage for the PrimeC composition, including patent grants in Brazil, the United States and Australia, as well as Nasdaq listing compliance notices, shareholder voting matters, capital-structure disclosures, governance updates, material agreements, and operating or financial results.
NeuroSense (NASDAQ: NRSN) announced a definitive agreement for a $600,000 insider-led private placement of 750,000 ordinary shares at $0.80 per share, a price 6.7% above the April 27, 2026 close. The offering includes $200,000 commitments each from CEO Alon Ben-Noon, CFO Or Eisenberg, and a significant existing shareholder. The private placement is expected to close during the week of May 3, 2026, is subject to customary closing conditions, and proceeds will be used for general corporate purposes ahead of upcoming clinical and regulatory milestones.
NeuroSense (NASDAQ: NRSN) announced that Brazil’s INPI granted Patent No. BR 112024007727-6 for its PrimeC composition, providing protection through October 2042. The grant follows corresponding U.S. (12,097,185) and Australian (2022370513) patents, strengthening the company’s global IP estate.
PrimeC is a fixed-dose oral combination of ciprofloxacin and celecoxib in an extended-release formulation. NeuroSense is preparing to initiate a Phase 3 pivotal PARAGON trial in ALS after positive Phase 2b PARADIGM results and FDA clearance, supporting longer-term development and potential commercialization.
NeuroSense (Nasdaq: NRSN) received Nasdaq notification letters on April 2, 2026, for noncompliance with the $1.00 minimum bid rule and the $35M minimum market value of listed securities (MVLS) rule after 30 consecutive business days below each threshold.
These notices do not affect current listing or trading. The company has until September 29, 2026 (180 days) to regain compliance by meeting each metric for 10 consecutive business days and is evaluating actions to restore compliance focused on long-term shareholder value.
NeuroSense (Nasdaq: NRSN) reported 2025 results and a business update. PrimeC advanced to a late-stage asset with FDA clearance to start the Phase 3 PARAGON trial and Phase 2b PARADIGM showed ~33% slowing of progression over 18 months.
In early 2026 the company reported a 65% reduction in risk of death and a >14-month median survival benefit; results were published in JAMA Neurology. Financials show $0.2M cash at Dec 31, 2025 and a $11.125M net loss for 2025. Key near-term milestones include a May 2026 pre-NDS meeting in Canada and Alzheimer’s readouts.
NeuroSense (NASDAQ:NRSN) updated regulatory and clinical progress for lead asset PrimeC. A Health Canada pre‑NDS meeting was rescheduled to May 2026 to include additional clinical, biomarker and survival data intended to strengthen the submission.
The company expects an Alzheimer's study clinical and biomarker readout in the coming weeks and cites a previously disclosed 65% reduction in risk of death and FDA clearance to start the pivotal Phase 3 PARAGON ALS trial.
NeuroSense (NASDAQ: NRSN) announced that Dr. Christian Lunetta will present new clinical and biomarker data on PrimeC for ALS at AD/PD 2026 in Copenhagen on March 19, 2026. The presentation reviews Phase 2b PARADIGM findings and biomarker analyses that informed the design of the planned global Phase 3 PARAGON trial.
PARADIGM data were recently published in JAMA Neurology, and NeuroSense says it is actively engaging regulators as PARAGON — a multinational, randomized, double-blind, placebo-controlled study — is advanced to further evaluate PrimeC's safety and efficacy.
NeuroSense (NASDAQ: NRSN) announced that Dr. Christian Lunetta will present new clinical and biomarker data on PrimeC for ALS at AD/PD™ 2026 on March 19, 2026 in Copenhagen.
The presentation reviews Phase 2b PARADIGM findings, cites publication in JAMA Neurology, and outlines plans for the multinational Phase 3 PARAGON trial while the company maintains regulatory engagement.
NeuroSense (NASDAQ: NRSN) announced JAMA Neurology publication of PARADIGM Phase 2b results for PrimeC in ALS, reporting slower functional decline, reduced complications, and biomarker activity.
Key findings: 7.92-point ALSFRS-R advantage at 18 months (~36% slowing, p=0.007), 64% relative reduction in ALS complications (p=0.02), favorable safety vs placebo, and modulation of iron and microRNA biomarkers.
NeuroSense (NASDAQ: NRSN) will present long-term survival data from the Phase 2b PARADIGM trial of PrimeC at the MDA Clinical & Scientific Conference on March 9, 2026. The analysis showed a 65% reduction in risk of death (HR 0.35; p=0.0037) and a >14-month median survival benefit (36.3 vs. 21.4 months; log-rank p=0.0218).
The randomized, double-blind, placebo-controlled study enrolled 68 participants (2:1 randomization) with a six-month double-blind period followed by an open-label extension; safety was described as favorable.
NeuroSense (NASDAQ: NRSN) reported extended PARADIGM Phase 2b survival data showing a median survival of 36.3 months with continuous PrimeC versus 21.4 months for initial placebo, an improvement of over 14 months (~70% increase).
Adjusted analysis showed a 65% reduction in risk of death (HR 0.35; 95% CI 0.17–0.71; p=0.0037) and a statistically significant log-rank p=0.0218. The randomized 68-patient trial included a 2:1 active:placebo double-blind period and an open-label extension; company engagement with regulators continues.